Therapeutics & Vaccines
Combination Therapy for the Treatment of Immune Checkpoint Blockade Resistant Cancers
WARF: P250217US02
Inventors: Deric Wheeler, Bridget Crossman, Ravi Salgia
The Invention
UW-Madison researchers in collaboration with a researcher at City of Hope Cancer Center developed a combination therapy that utilizes Keytruda and a clinically approved receptor tyrosine kinase inhibitor to treat cancer. They showed that dosed separately, neither Keytruda nor the kinase inhibitor stopped tumor growth in a model for head and neck cancer. However, when given together, the two treatments displayed a dramatic effect on tumor growth.
Tech Fields
For current licensing status, please contact Rafael Diaz at [javascript protected email address] or 608-960-9847